Search

Your search keyword '"Berton Rigaud, Dominique"' showing total 277 results
Start Over Author "Berton Rigaud, Dominique"
277 results on '"Berton Rigaud, Dominique"'

1. The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research

Author

Moniot, Aurélie, Schneider, Christophe, Chardin, Laure, Yaniz-Galende, Elisa, Genestie, Catherine, Etiennot, Marion, Henry, Aubéri, Drelon, Coralie, Le Formal, Audrey, Langlois, Benoit, Venat, Laurence, Louvet, Christophe, Favier, Laure, Lortholary, Alain, Berton-Rigaud, Dominique, Dohollou, Nadine, Desauw, Christophe, Fabbro, Michel, Malaurie, Emmanuelle, Dubot, Coraline, Kurtz, Jean Emmanuel, Bonichon Lamichhane, Nathalie, Pujade-Lauraine, Éric, Jeanne, Albin, Leary, Alexandra, and Dedieu, Stéphane

Published
2024
Full Text
View/download PDF

2. Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from the randomized phase II trial CHIVA (GINECO).

Author

Corbaux, Pauline, primary, Colomban, Olivier, additional, Lescuyer, Gaelle, additional, Haon, Christine, additional, Ray-Coquard, Isabelle Laure, additional, De Rauglaudre, Gaetan, additional, Joly, Florence, additional, Abdeddaim, Cyril, additional, Combe, Pierre, additional, Lortholary, Alain, additional, Hamizi, Salima, additional, Deldycke, Clothilde, additional, Ferron, Gwenael, additional, Meunier, Jérôme, additional, Alexandre, Jerome, additional, Berton-Rigaud, Dominique, additional, Kaminsky, Marie-Christine, additional, Pujade-Lauraine, Eric, additional, Payen, Lea, additional, and You, Benoit, additional

Published
2024
Full Text
View/download PDF

3. Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy

Author

Yaniz-Galende, Elisa, primary, Zeng, Qinghe, additional, Grau-Bejar, Juan Francisco, additional, Klein, Christophe, additional, Blanc-Durand, Félix, additional, Le Formal, Audrey, additional, Pujade-Lauraine, Eric, additional, Chardin, Laure, additional, Edmond, Elodie, additional, Marty, Virginie, additional, Ray-Coquard, Isabelle, additional, Joly, Florence, additional, Ferron, Gwenaël, additional, Pautier, Patricia, additional, Berton-Rigaud, Dominique, additional, Lortholary, Alain, additional, Dohollou, Nadine, additional, Desauw, Christophe, additional, Fabbro, Michel, additional, Malaurie, Emmanuelle, additional, Bonichon-Lamichhane, Nathalie, additional, Bello Roufai, Diana, additional, Gantzer, Justine, additional, Rouleau, Etienne, additional, Genestie, Catherine, additional, and Leary, Alexandra, additional

Published
2024
Full Text
View/download PDF

4. Management of Rare Uterine Malignant Tumors

Author

Amant, Frederic, Hensley, Martee, Pautier, Patricia, Friedlander, Michael, Sagae, Satoru, Fujiwara, Keiichi, Berton Rigaud, Dominique, Lorusso, Domenica, Ray-Coquard, Isabelle, and Mirza, Mansoor R., editor

Published
2020
Full Text
View/download PDF

5. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)

Author

Robelin, Patrick, Tod, Michel, Colomban, Olivier, Lachuer, Joel, Ray-Coquard, Isabelle, Rauglaudre, Gaëtan De, Joly, Florence, Chevalier-Place, Annick, Combe, Pierre, Lortholary, Alain, Hamizi, Salima, Raban, Nadia, Ferron, Gwénaël, Meunier, Jérôme, Berton-Rigaud, Dominique, Alexandre, Jérôme, Kaminsky, Marie-Christine, Dubot, Coraline, Leary, Alexandra, Malaurie, Emmanuelle, and You, Benoit

Published
2020
Full Text
View/download PDF

6. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Author

Ackermann, Sven, Anthuber, Christoph, Aydogdu, Mustafa, Baldauf, Angelika, Bauer, Wolfgang, Behringer, Dirk, Belau, Antje, Bender, Alexandra, Brucker, Cosima, Burges, Alexander, Canzler, Ulrich, Daabach, Trygve, Denschlag, Dominik, Deryal, Mustafa, Dörfel, Steffen, Ebert, Juliane, El-Balat, Ahmed, Fehm, Tanja, Feidicker, Susanne Maria, Feisel-Schwickardi, Gabriele, Felberbaum, Ricardo, Frank, Matthias, Gebauer, Gerhard, Gerber, Bernd, Gerhardt, Axel, Grafe, Andrea, Griesshammer, Martin, Grischke, Eva-Maria, Gröll, Isolde, Gropp-Meier, Martina, Hager, Dietrich, Hanf, Volker, Hannig, Carla Verena, Hantschmann, Peer, Harter, Philipp, Hauzenberger, Tanja, Herwig, Uwe, Heubner, Martin, Hielscher, Carsten, Hilpert, Felix, Hitschold, Thomas, Hofmann, Manfred, Jackisch, Christian, Janni, Wolfgang, Kiesel, Ludwig, Ko, Yon-Dschun, Koch, Hans-Joachim, Krabisch, Petra, Krieger, Peter, Kubin, Thomas, Kühn, Thorsten, Lampe, Björn, Ledwon, Peter, Lemster, Sabine, Lex, Benno, Liebrich, Clemens, Lorenz, Ralf, Lück, Hans-Joachim, Mahner, Sven, Mallmann, Peter, Marmé, Frederik, Meier, Werner, Meinerz, Wolfgang, Menke, Götz, Möbus, Volker, Müller, Thomas, Müller, Volker, Neunhöffer, Tanja, Ober, Angelika, Oskay-Özcelik, Gülten, Ostertag, Horst, Park-Simon, Tjoung-Won, Pölcher, Martin, Rautenberg, Beate, Rein, Daniel, Reiter, Wilhelm, Rempen, Andreas, Runnebaum, Ingo, Schmalfeldt, Barbara, Schmidt, Marcus, Schnohr, Sabine, Scholz, Heinz, Schröder, Willibald, Sehouli, Jalid, Simon, Eike, Sperfeld, Antje, Steckkönig, Annette, Strauß, Hans-Georg, Stuth, Ronaldo, Terhaag, Jürgen, Thiel, Falk, Thill, Marc, Tomé, Oliver, Uleer, Christoph, Vogel, Susanne, Voß, Hermann, Weigel, Michael, Winkler, Ulrich, Wischnik, Arthur, Zeiser, Tobias, Zorr, Andreas, Glasspool, Ros, Hudson, Emma, Jones, Rachel, Lafleur, Judith, Marth, Christian, Petru, Edgar, Reinthaller, Alexander, Antill, Yoland, Azer, Mary, Baron-Hay, Sally, Beale, Philip, Begbie, Stephen, Black, Allison, Briscoe, Karen, Dean, Andrew, Goh, Jeffrey, Harvey, Sandra, Lee, Chee, Matos, Marco, Meniawy, Tarek, Olesen, Inger, Shannon, Catherine, Vasey, Paul, Abadie-Lacourtoisie, Sophie, Arsene, Olivier, Barthier, Sophie, Becuwe-Roemer, Célia, Berton-Rigaud, Dominique, Cappiello-Bataller, Maria, Catala, Stéphanie, Costan, Cristina, Del Piano, Francesco, Deplanque, Gaël, Despax, Raymond, Dohollou, Nadine, Garnier-Tixidré, Claire, Grenier, Julien, Guardiola, Emmanuel, Hardy-Bessard, Anne-Claire, Joly, Florence, Kurtz, Jean-Emmanuel, Lefeuvre-Plesse, Claudia, Leheurteur, Marianne, Lesoin, Anne, Levache, Charles-Briac, L'Haridon, Tifenn, Longo, Raffaele, Lortholary, Alain, Meunier, Jérôme, Mouret-Reynier, Marie-Ange, Petit, Thierry, Raban, Nadia, Romano, Olivier, Vannetzel, Jean-Michel, Zannetti, Alain, Pfisterer, Jacobus, Shannon, Catherine M, Baumann, Klaus, Rau, Joern, Dean, Andrew P, Hein, Alexander, Zeimet, Alain G, Hanker, Lars C, Glasspool, Rosalind, de Gregorio, Nikolaus, Meniawy, Tarek M, Goh, Jeffrey C, Baron Hay, Sally, Kommoss, Stefan, and du Bois, Andreas

Published
2020
Full Text
View/download PDF

7. “Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”

Author

Gernier, François, Ahmed-Lecheheb, Djihane, Pautier, Patricia, Floquet, Anne, Nadeau, Cédric, Frank, Sophie, Alexandre, Jérôme, Selle, Frédéric, Berton-Rigaud, Dominique, Kalbacher, Elsa, Orfeuvre, Hubert, Lortholary, Alain, Augereau, Paule, Labombarda, Fabien, Perrier, Lionel, Grellard, Jean-Michel, Licaj, Idlir, Clarisse, Bénédicte, Savoye, Aude-Marie, Bourien, Héloise, De La Motte Rouge, Thibaut, Kurtz, Jean-Emmanuel, Kerdja, Katia, Lelaidier, Anaïs, Charreton, Amandine, Ray-Coquard, Isabelle, and Joly, Florence

Published
2021
Full Text
View/download PDF

9. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial

Author

Romeo, Clémence, Joly, Florence, Ray-Coquard, Isabelle, El Kouri, Claude, Mercier-Blas, Anne, Berton-Rigaud, Dominique, Kalbacher, Elsa, Cojocarasu, Oana, Fabbro, Michel, Cretin, Jacques, Zannetti, Alain, Abadie-Lacourtoisie, Sophie, Mollon, Delphine, Hardy-Bessard, Anne-Claire, Provansal, Magali, Blot, Emmanuel, Delbaldo, Catherine, Lesoin, Anne, Freyer, Gilles, and You, Benoît

Published
2019
Full Text
View/download PDF

10. #208 Metabolic syndrome, long-term fatigue and inflammation in epithelial ovarian cancer survivors: vivrovaire, ancillary study

Author

Desbois, Pauline, primary, Neviere, Zoe, additional, Mauff, Brigitte Le, additional, Dauda, Mohammed Sali, additional, Gernier, François, additional, Grellard, Jean-Michel, additional, Pautier, Patricia, additional, Kalbacher, Elsa, additional, Floquet, Anne, additional, Berton-Rigaud, Dominique, additional, Abadie-Lacourtoisie, Sophie, additional, Tredan, Olivier, additional, Rousset-Jablonski, Christine, additional, Follana, Philippe, additional, Alexandre, Jerome, additional, Zanetti, Alain, additional, Dohollou, Nadine, additional, Clarisse, Benedicte, additional, Joly, Florence, additional, and Cherifi, François, additional

Published
2023
Full Text
View/download PDF

11. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

Author

GCIG Symptom Benefit group, King, Madeleine T., Stockler, Martin R., O'Connell, Rachel L., Buizen, Luke, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Bryce, Jane, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sehouli, Jalid, Feeney, Amanda, Berton-Rigaud, Dominique, Costa, Daniel S. J., and Friedlander, Michael L.

Published
2018

13. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)

Author

Roncolato, Felicia T., Berton-Rigaud, Dominique, O'Connell, Rachel, Lanceley, Anne, Sehouli, Jalid, Buizen, Luke, Okamoto, Aikou, Aotani, Eriko, Lorusso, Domenica, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan, Hilpert, Felix, Ledermann, Jonathan A., Kaminsky, Marie Christine, Stockler, Martin R., King, Madeleine T., and Friedlander, Michael

Published
2018
Full Text
View/download PDF

14. Management of Rare Uterine Malignant Tumors

Author

Amant, Frederic, primary, Hensley, Martee, additional, Pautier, Patricia, additional, Friedlander, Michael, additional, Sagae, Satoru, additional, Fujiwara, Keiichi, additional, Berton Rigaud, Dominique, additional, Lorusso, Domenica, additional, and Ray-Coquard, Isabelle, additional

Published
2019
Full Text
View/download PDF

15. Figure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

17. FIGURE 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

18. FIGURE 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

19. FIGURE 4 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

20. FIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

21. Data from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

24. Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, additional, Pommier, Roxane M., additional, Treilleux, Isabelle, additional, Boyault, Sandrine, additional, Devouassoux-Shisheboran, Mojgan, additional, Kielbassa, Janice, additional, Thomas, Emilie, additional, Tonon, Laurie, additional, Le Texier, Vincent, additional, Charreton, Amandine, additional, Morel, Anne-Pierre, additional, Floquet, Anne, additional, Joly, Florence, additional, Berton-Rigaud, Dominique, additional, Ferron, Gwenaël, additional, Arnould, Laurent, additional, Croce, Sabrina, additional, Bataillon, Guillaume, additional, Saintigny, Pierre, additional, Mery-Lamarche, Eliane, additional, Sagan, Christine, additional, Senaratne, Aruni P., additional, Gut, Ivo G., additional, Calvo, Fabien, additional, Viari, Alain, additional, Ouzounova, Maria, additional, Ray-Coquard, Isabelle, additional, and Puisieux, Alain, additional

Published
2023
Full Text
View/download PDF

25. supplementary table 2 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

Author

de la Rochefordiere, Anne, primary, Kamal, Maud, primary, Floquet, Anne, primary, Thomas, Laurence, primary, Petrow, Peter, primary, Petit, Thierry, primary, Pop, Marius, primary, Fabbro, Michel, primary, Kerr, Christine, primary, Joly, Florence, primary, Sevin, Emmanuel, primary, Maillard, Sophie, primary, Curé, Hervé, primary, Weber, Béatrice, primary, Brunaud, Claire, primary, Minsat, Mathieu, primary, Gonzague, Laurence, primary, Berton-Rigaud, Dominique, primary, Aumont, Maud, primary, Gladieff, Laurence, primary, Peignaux, Karine, primary, Bernard, Virginie, primary, Leroy, Quentin, primary, Bieche, Ivan, primary, Margogne, Audrey, primary, Nadan, AnaTereza, primary, Fourchotte, Virginie, primary, Diallo, Alhassane, primary, Asselain, Benard, primary, Plancher, Corine, primary, Armanet, Sébastien, primary, Beuzeboc, Philippe, primary, and Scholl, Suzy M., primary

Published
2023
Full Text
View/download PDF

26. supplementary table 4 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

Author

de la Rochefordiere, Anne, primary, Kamal, Maud, primary, Floquet, Anne, primary, Thomas, Laurence, primary, Petrow, Peter, primary, Petit, Thierry, primary, Pop, Marius, primary, Fabbro, Michel, primary, Kerr, Christine, primary, Joly, Florence, primary, Sevin, Emmanuel, primary, Maillard, Sophie, primary, Curé, Hervé, primary, Weber, Béatrice, primary, Brunaud, Claire, primary, Minsat, Mathieu, primary, Gonzague, Laurence, primary, Berton-Rigaud, Dominique, primary, Aumont, Maud, primary, Gladieff, Laurence, primary, Peignaux, Karine, primary, Bernard, Virginie, primary, Leroy, Quentin, primary, Bieche, Ivan, primary, Margogne, Audrey, primary, Nadan, AnaTereza, primary, Fourchotte, Virginie, primary, Diallo, Alhassane, primary, Asselain, Benard, primary, Plancher, Corine, primary, Armanet, Sébastien, primary, Beuzeboc, Philippe, primary, and Scholl, Suzy M., primary

Published
2023
Full Text
View/download PDF

27. supplementary table 1 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

Author

de la Rochefordiere, Anne, primary, Kamal, Maud, primary, Floquet, Anne, primary, Thomas, Laurence, primary, Petrow, Peter, primary, Petit, Thierry, primary, Pop, Marius, primary, Fabbro, Michel, primary, Kerr, Christine, primary, Joly, Florence, primary, Sevin, Emmanuel, primary, Maillard, Sophie, primary, Curé, Hervé, primary, Weber, Béatrice, primary, Brunaud, Claire, primary, Minsat, Mathieu, primary, Gonzague, Laurence, primary, Berton-Rigaud, Dominique, primary, Aumont, Maud, primary, Gladieff, Laurence, primary, Peignaux, Karine, primary, Bernard, Virginie, primary, Leroy, Quentin, primary, Bieche, Ivan, primary, Margogne, Audrey, primary, Nadan, AnaTereza, primary, Fourchotte, Virginie, primary, Diallo, Alhassane, primary, Asselain, Benard, primary, Plancher, Corine, primary, Armanet, Sébastien, primary, Beuzeboc, Philippe, primary, and Scholl, Suzy M., primary

Published
2023
Full Text
View/download PDF

28. supplementary table 3 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

Author

de la Rochefordiere, Anne, primary, Kamal, Maud, primary, Floquet, Anne, primary, Thomas, Laurence, primary, Petrow, Peter, primary, Petit, Thierry, primary, Pop, Marius, primary, Fabbro, Michel, primary, Kerr, Christine, primary, Joly, Florence, primary, Sevin, Emmanuel, primary, Maillard, Sophie, primary, Curé, Hervé, primary, Weber, Béatrice, primary, Brunaud, Claire, primary, Minsat, Mathieu, primary, Gonzague, Laurence, primary, Berton-Rigaud, Dominique, primary, Aumont, Maud, primary, Gladieff, Laurence, primary, Peignaux, Karine, primary, Bernard, Virginie, primary, Leroy, Quentin, primary, Bieche, Ivan, primary, Margogne, Audrey, primary, Nadan, AnaTereza, primary, Fourchotte, Virginie, primary, Diallo, Alhassane, primary, Asselain, Benard, primary, Plancher, Corine, primary, Armanet, Sébastien, primary, Beuzeboc, Philippe, primary, and Scholl, Suzy M., primary

Published
2023
Full Text
View/download PDF

29. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

Author

King, Madeleine T., Stockler, Martin R., O’Connell, Rachel L., Buizen, Luke, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Bryce, Jane, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sehouli, Jalid, Feeney, Amanda, Berton-Rigaud, Dominique, Costa, Daniel S. J., Friedlander, Michael L., and for the GCIG Symptom Benefit group

Published
2017
Full Text
View/download PDF

30. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study

Author

Harter, Philipp, Johnson, Toby, Berton-Rigaud, Dominique, Park, Sang-Yoon, Friedlander, Michael, del Campo, Josep M., Shimada, Muneaki, Forget, Frédéric, Mirza, Mansoor R., Colombo, Nicoletta, Zamagni, Claudio, Chan, John K., Imhof, Martin, Herzog, Thomas J., O'Donnell, Dearbhaile, Heitz, Florian, King, Karen, Stinnett, Sandy, Barrett, Catherine, Jobanputra, Minesh, Xu, Chun-Fang, and du Bois, Andreas

Published
2016
Full Text
View/download PDF

31. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

Author

Lorusso, Domenica, Hilpert, Felix, González Martin, Antonio, Rau, Joern, Ottevanger, Petronella, Greimel, Elfriede, Lück, Hans-Joachim, Selle, Frédéric, Colombo, Nicoletta, Kroep, Judith R, Mirza, Mansoor R, Berger, Regina, Pardo, Beatriz, Grischke, Eva-Maria, Berton-Rigaud, Dominique, Martinez-Garcia, Jeronimo, Vergote, Ignace, Redondo, Andrés, Cardona, Andrés, Bastière-Truchot, Lydie, du Bois, Andreas, and Kurzeder, Christian

Published
2019
Full Text
View/download PDF

33. Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network

Author

Bonsang-Kitzis, Hélène, primary, Panchbhaya, Nabilah, additional, Bats, Anne-Sophie, additional, Pujade-Lauraine, Eric, additional, Pautier, Patricia, additional, Ngô, Charlotte, additional, Le Frère-Belda, Marie-Aude, additional, Kalbacher, Elsa, additional, Floquet, Anne, additional, Berton-Rigaud, Dominique, additional, Lefeuvre-Plesse, Claudia, additional, Fabbro, Michel, additional, Ray-Coquard, Isabelle, additional, and Lécuru, Fabrice, additional

Published
2022
Full Text
View/download PDF

36. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study

Author

Sehouli, Jalid, Pietzner, Klaus, Wimberger, Pauline, Vergote, Ignace, Rosenberg, Per, Schneeweiss, Andreas, Bokemeyer, Carsten, Salat, Christoph, Scambia, Giovanni, Berton-Rigaud, Dominique, Santoro, Armando, Cervantes, Andrés, Trédan, Olivier, Tournigand, Christophe, Colombo, Nicoletta, Dudnichenko, Alexander S., Westermann, Anneke, Friccius-Quecke, Hilke, and Lordick, Florian

Published
2014
Full Text
View/download PDF

40. 268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)

Author

Berton-Rigaud, Dominique, primary, Vergote, Ignace, additional, Pautier, Patricia, additional, Kryzhanivska, Anna, additional, Angelergues, Antoine, additional, Kornacki, Deanna, additional, Dudzisz-Sledz, Monika, additional, Tian, Chuan, additional, Bourayou, Nawel, additional, and Selle, Frederic, additional

Published
2020
Full Text
View/download PDF

41. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Author

Pfisterer, Jacobus, primary, Shannon, Catherine M, additional, Baumann, Klaus, additional, Rau, Joern, additional, Harter, Philipp, additional, Joly, Florence, additional, Sehouli, Jalid, additional, Canzler, Ulrich, additional, Schmalfeldt, Barbara, additional, Dean, Andrew P, additional, Hein, Alexander, additional, Zeimet, Alain G, additional, Hanker, Lars C, additional, Petit, Thierry, additional, Marmé, Frederik, additional, El-Balat, Ahmed, additional, Glasspool, Rosalind, additional, de Gregorio, Nikolaus, additional, Mahner, Sven, additional, Meniawy, Tarek M, additional, Park-Simon, Tjoung-Won, additional, Mouret-Reynier, Marie-Ange, additional, Costan, Cristina, additional, Meier, Werner, additional, Reinthaller, Alexander, additional, Goh, Jeffrey C, additional, L'Haridon, Tifenn, additional, Baron Hay, Sally, additional, Kommoss, Stefan, additional, du Bois, Andreas, additional, Kurtz, Jean-Emmanuel, additional, Ackermann, Sven, additional, Anthuber, Christoph, additional, Aydogdu, Mustafa, additional, Baldauf, Angelika, additional, Bauer, Wolfgang, additional, Behringer, Dirk, additional, Belau, Antje, additional, Bender, Alexandra, additional, Brucker, Cosima, additional, Burges, Alexander, additional, Daabach, Trygve, additional, Denschlag, Dominik, additional, Deryal, Mustafa, additional, Dörfel, Steffen, additional, Ebert, Juliane, additional, Fehm, Tanja, additional, Feidicker, Susanne Maria, additional, Feisel-Schwickardi, Gabriele, additional, Felberbaum, Ricardo, additional, Frank, Matthias, additional, Gebauer, Gerhard, additional, Gerber, Bernd, additional, Gerhardt, Axel, additional, Grafe, Andrea, additional, Griesshammer, Martin, additional, Grischke, Eva-Maria, additional, Gröll, Isolde, additional, Gropp-Meier, Martina, additional, Hager, Dietrich, additional, Hanf, Volker, additional, Hannig, Carla Verena, additional, Hantschmann, Peer, additional, Hauzenberger, Tanja, additional, Herwig, Uwe, additional, Heubner, Martin, additional, Hielscher, Carsten, additional, Hilpert, Felix, additional, Hitschold, Thomas, additional, Hofmann, Manfred, additional, Jackisch, Christian, additional, Janni, Wolfgang, additional, Kiesel, Ludwig, additional, Ko, Yon-Dschun, additional, Koch, Hans-Joachim, additional, Krabisch, Petra, additional, Krieger, Peter, additional, Kubin, Thomas, additional, Kühn, Thorsten, additional, Lampe, Björn, additional, Ledwon, Peter, additional, Lemster, Sabine, additional, Lex, Benno, additional, Liebrich, Clemens, additional, Lorenz, Ralf, additional, Lück, Hans-Joachim, additional, Mallmann, Peter, additional, Meinerz, Wolfgang, additional, Menke, Götz, additional, Möbus, Volker, additional, Müller, Thomas, additional, Müller, Volker, additional, Neunhöffer, Tanja, additional, Ober, Angelika, additional, Oskay-Özcelik, Gülten, additional, Ostertag, Horst, additional, Pölcher, Martin, additional, Rautenberg, Beate, additional, Rein, Daniel, additional, Reiter, Wilhelm, additional, Rempen, Andreas, additional, Runnebaum, Ingo, additional, Schmidt, Marcus, additional, Schnohr, Sabine, additional, Scholz, Heinz, additional, Schröder, Willibald, additional, Simon, Eike, additional, Sperfeld, Antje, additional, Steckkönig, Annette, additional, Strauß, Hans-Georg, additional, Stuth, Ronaldo, additional, Terhaag, Jürgen, additional, Thiel, Falk, additional, Thill, Marc, additional, Tomé, Oliver, additional, Uleer, Christoph, additional, Vogel, Susanne, additional, Voß, Hermann, additional, Weigel, Michael, additional, Winkler, Ulrich, additional, Wischnik, Arthur, additional, Zeiser, Tobias, additional, Zorr, Andreas, additional, Glasspool, Ros, additional, Hudson, Emma, additional, Jones, Rachel, additional, Lafleur, Judith, additional, Marth, Christian, additional, Petru, Edgar, additional, Antill, Yoland, additional, Azer, Mary, additional, Baron-Hay, Sally, additional, Beale, Philip, additional, Begbie, Stephen, additional, Black, Allison, additional, Briscoe, Karen, additional, Dean, Andrew, additional, Goh, Jeffrey, additional, Harvey, Sandra, additional, Lee, Chee, additional, Matos, Marco, additional, Meniawy, Tarek, additional, Olesen, Inger, additional, Shannon, Catherine, additional, Vasey, Paul, additional, Abadie-Lacourtoisie, Sophie, additional, Arsene, Olivier, additional, Barthier, Sophie, additional, Becuwe-Roemer, Célia, additional, Berton-Rigaud, Dominique, additional, Cappiello-Bataller, Maria, additional, Catala, Stéphanie, additional, Del Piano, Francesco, additional, Deplanque, Gaël, additional, Despax, Raymond, additional, Dohollou, Nadine, additional, Garnier-Tixidré, Claire, additional, Grenier, Julien, additional, Guardiola, Emmanuel, additional, Hardy-Bessard, Anne-Claire, additional, Lefeuvre-Plesse, Claudia, additional, Leheurteur, Marianne, additional, Lesoin, Anne, additional, Levache, Charles-Briac, additional, Longo, Raffaele, additional, Lortholary, Alain, additional, Meunier, Jérôme, additional, Raban, Nadia, additional, Romano, Olivier, additional, Vannetzel, Jean-Michel, additional, and Zannetti, Alain, additional

Published
2020
Full Text
View/download PDF

42. Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography

Author

Rousseau, Caroline, Devillers, Anne, Sagan, Christine, Ferrer, Ludovic, Bridji, Boumédiène, Campion, Loïc, Ricaud, Myriam, Bourbouloux, Emmanuelle, Doutriaux, Isabelle, Clouet, Martine, Berton-Rigaud, Dominique, Bouriel, Catherine, Delecroix, Valérie, Garin, Etienne, Rouquette, Sophie, Resche, Isabelle, Kerbrat, Pierre, Chatal, Jean François, and Campone, Mario

Published
2006
Full Text
View/download PDF

43. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: Results of the French Adjuvant Study Group

Author

Benchalal, Mohamed, Le Prisé, Elisabeth, de Lafontan, Brigitte, Berton-Rigaud, Dominique, Belkacemi, Yazid, Romestaing, Pascale, Peignaux, Karine, Courdi, Adel, Monnier, Alain, Montcuquet, Philippe, Goudier, Marie-Josèphe, Marchal, Christian, Chollet, Philippe, Abadie-Lacourtoisie, Sophie, Datchary, Jean, Veyret, Corinne, and Kerbrat, Pierre

Published
2005
Full Text
View/download PDF

44. Pertuzumab for the treatment of breast cancer

Author

Robert, Marie, primary, Frenel, Jean-Sébastien, additional, Bourbouloux, Emmanuelle, additional, Berton Rigaud, Dominique, additional, Patsouris, Anne, additional, Augereau, Paule, additional, Gourmelon, Carole, additional, and Campone, Mario, additional

Published
2019
Full Text
View/download PDF

45. Pooled analysis of onapristone extended release (ONA ER) in metastatic cancer patients (pts): A review of liver safety.

Author

Cottu, Paul H., primary, Jayaram, Anuradha, additional, Italiano, Antoine, additional, Pacey, Simon, additional, Leary, Alexandra, additional, Jones, Robert J, additional, Campone, Mario, additional, Floquet, Anne, additional, Berton Rigaud, Dominique, additional, Lhomme, Catherine, additional, Sablin, Marie-Paule, additional, Bexon, Alice Susannah, additional, Bonneterre, Jacques, additional, Attard, Gerhardt, additional, and Watkins, Paul B, additional

Published
2019
Full Text
View/download PDF

46. Menopausal symptoms in epithelial ovarian cancer survivors: The GINECO VIVROVAIRE2 study.

Author

Joly, Florence, primary, Pautier, Patricia, additional, Kalbacher, Elsa, additional, Gernier, François, additional, Fauvet, Raffaele, additional, Floquet, Anne, additional, Berton-Rigaud, Dominique, additional, Tredan, Olivier, additional, Follana, Philippe, additional, Alexandre, Jerome, additional, Zannetti, Alain, additional, Dohollou, Nadine, additional, Trager, Stephanie, additional, Licaj, Idlir, additional, Grellard, Jean-Michel, additional, Clarisse, Bénédicte, additional, Ahmed-Lecheheb, Djihane, additional, Rousset-Jablonski, Christine, additional, and Gompel, Anne, additional

Published
2019
Full Text
View/download PDF

48. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) : Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)

Author

Roncolato, Felicia T, Berton-Rigaud, Dominique, O'Connell, Rachel, Lanceley, Anne, Sehouli, Jalid, Buizen, Luke, Okamoto, Aikou, Aotani, Eriko, Lorusso, Domenica, Donnellan, Paul, Oza, Amit, Åvall-Lundqvist, Elisabeth, Berek, Jonathan, Hilpert, Felix, Ledermann, Jonathan A, Kaminsky, Marie Christine, Stockler, Martin R, King, Madeleine T, Friedlander, Michael, Roncolato, Felicia T, Berton-Rigaud, Dominique, O'Connell, Rachel, Lanceley, Anne, Sehouli, Jalid, Buizen, Luke, Okamoto, Aikou, Aotani, Eriko, Lorusso, Domenica, Donnellan, Paul, Oza, Amit, Åvall-Lundqvist, Elisabeth, Berek, Jonathan, Hilpert, Felix, Ledermann, Jonathan A, Kaminsky, Marie Christine, Stockler, Martin R, King, Madeleine T, and Friedlander, Michael

Abstract

BACKGROUND: Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The aim was to determine validity of mGPS in ROC, investigate its associations with health related quality of life (HRQL) and ECOG performance status (PS). METHODS: mGPS is based on serum C reactive protein (CRP) and albumin, with scores ranging from 0 (least) to 2 (most). HRQL was measured with EORTC QLQ C-30 and OV-28. χ2 tests for trend were used to examine the relationship between HRQL, PS and mGPS. Cox proportional hazards regression was used to assess associations between mGPS, HRQL, clinicopathological factors, and overall survival (OS). RESULTS: Inflammatory markers were available in 516 of 948 patients in GCIG SBS. 200(39%) had potentially platinum sensitive ROC with ≥3 lines of chemotherapy, 316(61%) had platinum resistant ROC. 282(55%), 123(24%), 111(22%) had mGPS of 0, 1, 2, respectively. Median OS (months) was 18.1, 9.6, and 6.6 for mGPS 0, 1, and 2 respectively. mGPS was an independent predictor of OS after adjusting for PS and platinum sensitivity (p<0.001). mGPS remained a predictor of OS after adjusting for physical function, role function, global health status, abdominal/GI symptoms, and multiple clinicopathologic factors (p=0.02). Worse PS and higher mGPS were associated with poorer HRQL (p<0.001). Higher mGPS was associated with worse HRQL, independent of PS. CONCLUSION: The mGPS is an independent predictor of OS in ROC after adjusting for HRQL and clinicopathological factors. Higher mGPS is associated with worse HRQL independent of PS. mGPS is simple, inexpensive and may be suitable for clinical practice, clinical trial patient selection and stratification.

Published
2018
Full Text
View/download PDF

49. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

Author

King, Madeleine T., Stockler, Martin R., OConnell, Rachel L., Buizen, Luke, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Bryce, Jane, Donnellan, Paul, Oza, Amit, Åvall-Lundqvist, Elisabeth, Berek, Jonathan S., Sehouli, Jalid, Feeney, Amanda, Berton-Rigaud, Dominique, Costa, Daniel S. J., Friedlander, Michael L., King, Madeleine T., Stockler, Martin R., OConnell, Rachel L., Buizen, Luke, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Bryce, Jane, Donnellan, Paul, Oza, Amit, Åvall-Lundqvist, Elisabeth, Berek, Jonathan S., Sehouli, Jalid, Feeney, Amanda, Berton-Rigaud, Dominique, Costa, Daniel S. J., and Friedlander, Michael L.

Abstract

Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed to review, revise, and validate a patient-reported outcome measure (PROM), the Measure of Ovarian Symptoms and Treatment concerns (MOST), developed in GCIG-SBS Stage 1 (MOSTv1, 35 items), and document recurrent ovarian cancer (ROC) symptom burden and benefit. GCIG-SBS Stage 2 recruited patients with platinum-resistant/refractory ROC (PRR-ROC) or potentially platinum-sensitive ROC with aeamp;lt;yenamp;gt; 3 lines of prior chemotherapy (PPS-ROC aeamp;lt;yenamp;gt; 3). Patients completed MOSTv1, QLQ-C30, QLQ-OV28, and FACT-O/FOSI at baseline and before cycle 3 of chemotherapy (pre-C3), and global assessments of change (MOST-Change) pre-C3. Clinicians rated patients cancer-related symptoms, performance status, and adverse events. Convergent and divergent validity (Spearmans correlations), discriminative validity (effect sizes between groups classified by clinician-rated characteristics), and responsiveness (paired t tests in patients expected to experience clinically meaningful change) were assessed. Of 948 recruits, 903 completed PROMs at baseline and 685 pre-C3. Baseline symptom burden was substantial for PRR-ROC and PPS-ROC aeamp;lt;yenamp;gt; 3. MOSTv2 has 24 items and five multi-item scales: abdominal symptoms (MOST-Abdo), disease or treatment-related symptoms (MOST-DorT), chemotherapy-related symptoms (MOST-Chemo), psychological symptoms (MOST-Psych), and MOST-Well-being. Correlations confirmed concurrent and divergent validity. Discriminative validity was confirmed by effect sizes that conformed with a priori hypotheses. MOST-Abdo was responsive to improvements in abdominal symptoms and MOST-Chemo detected the adverse effects of chemotherapy. The MOSTv2 validly quantifies patient-reported symptom burden, adverse effects, and symptom benefit in ROC, and as such is fit-for-purpose for clinical trials of palliative chemotherapy in ROC. Further research is required to assess test-retest reli, Funding Agencies|NHMRC [1063012, 570,893]; Target Ovarian Cancer [UCL-P001AL]; Cancer Research UK [C444/A15953]; UCL Cancer Trials Centre [C444/A15953]; Australian Government through Cancer Australia; NHMRC; Department of Health

Published
2018
Full Text
View/download PDF

50. Pertuzumab for the treatment of breast cancer.

Author

Robert, Marie, Frenel, Jean-Sébastien, Bourbouloux, Emmanuelle, Berton Rigaud, Dominique, Patsouris, Anne, Augereau, Paule, Gourmelon, Carole, and Campone, Mario

Subjects
BREAST cancer, EPIDERMAL growth factor receptors, METASTATIC breast cancer, CANCER treatment, MONOCLONAL antibodies, CELL receptors, COMBINED modality therapy, BREAST tumors, DRUG resistance in cancer cells
Abstract

Introduction: Pertuzumab, a humanized monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2), inhibits the heterodimerization of HER2 with other HER receptors. It has been approved both by the Food and Drug Administration and the European Medicine Agency in the metastatic, neoadjuvant and adjuvant setting.Areas covered: This review analyses and discusses preclinical and clinical studies of pertuzumab in breast cancer. In this article, we review the status of pertuzumab, the completed and ongoing trials, and its safety.Expert opinion: Pertuzumab is a key drug for the treatment of HER2-positive metastatic or early breast cancer. However, it is imperative to identify patients that will need dual-targeting and mechanisms of resistance. Moreover, the value of pertuzumab beyond progression needs to be evaluated. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results